UNH
XLV
A beat, and then some
UnitedHealth showed up with a cleaner-than-expected quarter: adjusted earnings came in at $7.23 a share, ahead of the $6.58 Wall Street was looking for, while revenue climbed 2% to $111.7 billion. That’s the kind of print that can wake up a stock that’s been stuck in the penalty box.
The real sugar rush: higher guidance
The bigger headline for investors wasn’t just the beat — it was the company lifting its 2026 adjusted EPS outlook to more than $18.25, up from a prior view of above $17.75. In plain English: management is seeing enough strength in the business to tell the market, “Relax, we’ve got this,” which is often what gets traders leaning in.
But the Medicare subplot isn’t going away
On Tuesday’s investor call, UnitedHealth also flagged some “challenges” around the Medicare Balance program tied to obesity drugs. That matters because policy and reimbursement changes can swing the economics of big health insurers faster than you can say “prior authorization.”
Why you should care
The stock jumped as investors cheered the earnings beat and the improved outlook, but this isn’t exactly a clean victory lap. The business still has to navigate Medicare program uncertainty, and that could keep a lid on how much love the market gives the name. Big picture: the quarter says UnitedHealth still has plenty of muscle — even if the policy treadmill never stops running.